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http://dx.doi.org/10.1016/j.ccr.2014.01.005SUMMARYMutations inKRAS are prevalent in human cancers and universally predictive of resistance to anticancer ther-
apeutics. Although it is widely accepted that acquisition of an activating mutation endows RAS genes with
functional autonomy, recent studies suggest that the wild-type forms of Ras may contribute to mutant
Ras-driven tumorigenesis. Here, we show that downregulation of wild-type H-Ras or N-Ras in mutant
K-Ras cancer cells leads to hyperactivation of the Erk/p90RSK and PI3K/Akt pathways and, consequently,
the phosphorylation of Chk1 at an inhibitory site, Ser 280. The resulting inhibition of ATR/Chk1 signaling
abrogates the activation of the G2 DNA damage checkpoint and confers specific sensitization of mutant
K-Ras cancer cells to DNA damage chemotherapeutic agents in vitro and in vivo.INTRODUCTION
Three closely related RAS oncogenes, HRAS, NRAS, and
KRAS, have been identified in mammals. These genes encode
small GTPases that function as molecular switches governing
the activation of a vast network of signaling pathways.
Growth factor signaling activates Ras by recruiting guanine
nucleotide exchange factors (GEFs) that catalyze the exchange
of guanosine diphosphate (GDP) for guanosine triphosphate
(GTP) (Bos et al., 2007). In turn, Ras activity is terminated
through GTP hydrolysis, which is greatly enhanced by
GTPase-accelerating proteins (GAPs). Hyperactivation of Ras,
which largely occurs through the acquisition of mutations that
hinder GTP hydrolysis, has been implicated in the etiology of
a wide number of human cancers. Overall, mutations in the
RAS genes have been associated with 30% of all human
tumors. Such mutations are generally limited to one of the
RAS genes, with KRAS being the most frequently mutated
and with the highest incidence in adenocarcinomas of the
pancreas (57%), colon (33%), and lung (17%) (Pylayeva-Gupta
et al., 2011).Significance
This study defines a functional dependence of K-Ras-driven
response and reveals a promising therapeutic strategy for th
mutant K-Ras cancer cells require wild-type H-Ras and N-Ras
checkpoint and that this dependence can be exploited to sp
inducing agents.
CThe critical role of oncogenic K-Ras as a drivingmutation in the
pathogenesis of cancer is supported by several genetically engi-
neeredmousemodels. Accordingly, expression of mutant K-Ras
alone is sufficient to drive malignant progression, whereas elim-
ination of mutant K-Ras from established tumors leads to tumor
regression (Chin et al., 1999; Fisher et al., 2001; Haigis et al.,
2008; Jackson et al., 2001; Li et al., 2011; Ying et al., 2012).
Because of its capacity to constitutively engage downstream
effector pathways, oncogenic K-Raswas initially thought to drive
the tumorigenic process independently of the wild-type forms.
However, it is becoming increasingly evident that the biological
outputs of oncogenic K-Ras are subject to a complex and
context-dependent modulation by wild-type Ras proteins.
Studies in chemically induced models of lung or skin tumorigen-
esis have demonstrated that the acquisition of an activating
mutation in a KRas or HRas allele is associated with loss of the
KRas wild-type or HRas wild-type allele, respectively (Bremner
and Balmain, 1990; Hegi et al., 1994; Zhang et al., 2001). Zhang
et al. (2001) further demonstrated that loss of the wild-type
KRas allele enhanced mutant K-Ras-driven tumorigenesis.
Together, these results suggest a tumor suppressive effect oftumors on wild-type H- and N-Ras for the DNA damage
e treatment of mutant K-Ras tumors. We demonstrate that
for the activation of the ATR-Chk1-mediated DNA damage
ecifically sensitize K-Ras-driven cancers to DNA damage-
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Figure 1. WT-H-Ras Knockdown Perturbs the Mitotic Progression of K-Ras Mutant Cancer Cells
(A) Isoform-specific knockdown of WT-H-Ras, WT-N-Ras, or WT-H- and N-Ras combined. DLD1 K-RasMut cells that harbor doxycycline-inducible shRNAs
directed at H-Ras (H-Ras sh 1, 2, 3), N-Ras (N-Ras sh 1, 2), H-Ras and N-Ras combined (H-Ras sh 1 and N-Ras sh 1), or scramble shRNA (Scr sh) were treated
with doxycycline for 96 hr. Whole-cell lysates (WCL) were immunoblotted for H-Ras, N-Ras, K-Ras, and tubulin (loading control).
(B) Effect of WT-H-Ras or WT-N-Ras suppression on the GTP-bound status of the remaining Ras isoforms. WCLs were subjected to GST-bound CRAF Ras-
binding domain (RBD) pull-downs and immunoblotted with the indicated antibodies.
(C and D) Effect of suppression of WT-H-Ras, WT-N-Ras, or WT-H- and N-Ras combined on the proliferation of DLD1 K-RasMut cells (C) and DLD1 K-RasKO cells
(D). The relative cell density was measured using a Syto60 stain and is expressed in arbitrary units (a.u.).
(E) Representative FACS histograms showing cell-cycle progression of synchronized control (Dox) and H-Ras-suppressed (+Dox) DLD1 K-RasMut cells that
harbor inducible H-Ras sh 3. Cells were released from a double thymidine block, fixed at the indicated time points, and FACS sorted for DNA content. Arrows
indicate the G2/M fraction at relevant time points. Data are representative of at least three independent experiments.
(F) Detection of mitotic fraction by FACS analysis of phosphorylated histone H3 (P-HH3)-positive cells in double-thymidine-release experiments as in (E).
(G) Representative images of mitotic aberrations (arrows) seen in WT-H-Ras-depleted DLD1 K-RasMut cells following a double-thymidine-release experiment as
in (E). Immunofluorescence images of cells stained for a-tubulin and DNA. Scale bar, 10 mm.
(legend continued on next page)
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Dependence of Mutant K-Ras Cancer Cells on WT-Rasthe wild-type Ras allele. Conversely, a recent study reported that
in mutant K-Ras-driven colorectal cancer, wild-type K-Ras
plays a tumor promoting role through counteracting mutant
K-Ras-induced apoptosis by mediating signaling from
mutant K-Ras-dependent autocrine-activated EGFR (Matalla-
nas et al., 2011).
Mutant K-Ras-driven cancers also retain the wild-type prod-
ucts of the remaining RAS genes, H- and NRAS, which appear
to synergize with mutant K-Ras in tumors of various tissues.
For example, enhanced levels of GTP-bound H-Ras and
N-Ras, due to mutant K-Ras-dependent nitrosylation of wild-
type H- and N-Ras, were shown to be required for the prolifera-
tion of mutant K-Ras cancer cells (Lim et al., 2008). A role for
wild-type H-Ras and N-Ras proteins in mediating RTK signaling
and proliferation of cancer cells that harbor mutant K-Ras has
also been demonstrated (Young et al., 2012). Moreover, Son of
Sevenless (Sos), a guanine nucleotide exchange factor (GEF)
for Ras and Rho GTPases, has been implicated in mutant Ras-
driven tumorigenesis (Jeng et al., 2012).
In the current study, we sought to determine the mechanisms
by which wild-type H-Ras and N-Ras proteins promote the
mutant K-Ras-driven tumorigenic phenotype.
RESULTS
Mutant K-Ras Cancer Cells RequireWild-Type H-Ras for
Proliferation and Progression through Mitosis
To investigate the functional relationship between mutant K-Ras
and wild-type (WT) H/N-Ras, we took the approach of specif-
ically suppressing the expression of WT-H-Ras and/or WT-
N-Ras, in cancer cells positive or negative for mutant K-Ras.
To this end, we initially employed the isogenic colon cancer cells
DLD-1 K-RasWT/G12D (DLD1 K-RasMut) and DLD1 K-RasWT/
(DLD1 K-RasKO), where the K-RASG12D allele has been knocked
out by homologous recombination (Luo et al., 2009b; Shirasawa
et al., 1993). These cell lines were engineered to harbor doxycy-
cline (Dox)-inducible small hairpin RNAs (shRNAs) directed at
H-Ras, N-Ras, or both H- and N-Ras. Accordingly, doxycycline
treatment specifically suppressed expression and activity of
the targeted isoforms, with no effect on the remaining isoforms
(Figures 1A and 1B; Figure S1A available online). As shown in
Figure 1C, individual knockdown of WT-H-Ras or WT-N-Ras in
DLD1 K-RasMut cells led to slower growth. Of note, no synergy
was observed upon knockdown of both WT-H-Ras and WT-
N-Ras, suggesting that the two WT-isoforms converge on the
same signaling module that regulates growth of DLD1 K-RasMut
cells (Figure 1C). In contrast, knockdown of either WT-H-Ras or
WT-N-Ras, or the two combined, in DLD1 K-RasKO cells, had no
effect on cell growth, indicating that the dependence on WT-H-
and/or N-Ras for cell growth is a specific property of mutant
K-Ras cancer cells (Figures 1D and S1A).
We next investigated whether the attenuated cell growth
observed upon WT-H-Ras and/or N-Ras knockdown in DLD1
K-RasMut cells could be the result of a slower progression(H) Scatter plots show the duration of mitosis, as determined by phase-contrast
Panc-1) and K-Ras WT (DLD1 K-RasKO and BxPC-3) cancer cells expressing scr
difference.
All experiments: error bars, mean ± SEM, n = 3, *p < 0.05, **p < 0.005, ***p < 0.0
Cthrough the cell cycle. Initially, we examined the cell-cycle pro-
gression of WT-H-Ras-suppressed DLD1 K-RasMut cells that
were synchronized at theG1/S border by double thymidine treat-
ment. Six hours after release, both WT-H-Ras-suppressed
(+Dox) and WT-H-Ras-intact (Dox) DLD1 K-RasMut cells had
completed replication and were predominantly in G2 as deter-
mined by the accumulation of cells with 4NDNA content (Figures
1E, 1F, and S1B). However, whereas the majority of WT-H-Ras-
intact cells completed mitosis and cell division and reached G1
over the next 4 hr, WT-H-Ras-suppressed cells showed a de-
layed transition through G2/M, as evident by the persistence of
cells with 4N DNA content (Figure 1E, arrows). Fluorescence-
activated cell sorting (FACS) analysis of phosphohistone
H3-positive cells revealed an increased mitotic index of WT-
H-Ras-suppressed cells relative to control (7–11 hr), suggesting
that the elevated fraction of 4N DNA content cells associated
with WT-H-Ras knockdown was due to a mitotic delay (Figures
1E and 1F). Consistent with this interpretation, WT-H-Ras-
suppressed DLD1 K-RasMut cells showed mitotic defects that
would preclude the timely satisfaction of the spindle checkpoint,
including misaligned and damaged chromosomes (Figure 1G).
To quantitatively measure themitotic delay within individual cells
and rule out the possibility that the observed mitotic aberrations
were due to the synchronization technique, we analyzed the
duration of mitosis in asynchronous cells by time-lapse phase-
contrast microscopy. We observed that WT-H-Ras knockdown
delayed mitotic progression in DLD1 K-RasMut cells (duration
of mitosis was 2 times longer compared to control), but not
in DLD1 K-RasKO cells (Figures 1H, S1C, and S1D). Similar
results were obtained when this analysis was extended to the
pancreatic cell line pair Panc-1 (K-Ras mutant) and BxPC-3
(K-Ras WT) (Figure 1H; Movies S1 and S2; Figures S1C and
S1D). Taken together, these data indicate that K-Ras mutant
cells specifically require WT-H-Ras for the timely progression
of mitosis.
Wild-Type H- and N-Ras Knockdown Enhance DNA
Damage in Mutant K-Ras Cancer Cells
In principle, the delay in mitosis and damaged chromosomes,
induced by WT-H-Ras knockdown, can be explained by misre-
gulation of the DNA damage response (DDR) (Rieder andMaiato,
2004; Brown and Baltimore, 2000; Lam et al., 2004; Lo¨ffler et al.,
2006; Zachos and Gillespie, 2007). A defective DDR would
compromise the ability of the cell to repair DNA damage, thereby
leading to an enhancement in the levels of DNA strand breaks
(Syljua˚sen et al., 2005; Toledo et al., 2011b). Evaluation of DNA
strand breaks by monitoring gH2AX staining revealed a signifi-
cant accumulation of gH2AX-positive cells upon knockdown of
WT-H-Ras in the DLD1-K-RasMut cells and a panel of K-Ras
mutant (Mut) pancreatic cancer cells (Panc-1, AsPC-1, PL45,
and MIA PaCa-2) (Figures 2A–2C). In contrast, gH2AX levels
remain unaltered when WT-H-Ras was knocked down in the
DLD1-K-RasKO and K-Ras WT pancreatic cancer cell lines
(BxPC-3 and Hs-700T), consistent with K-Ras Mut cancer cellstime-lapse microscopy, in asynchronous K-Ras Mut (DLD1 K-RasMut cells and
amble or H-Ras shRNAs. ****p < 0.0001 by Student’s t test; NS, no significant
005. See also Movies S1 and S2 and Figure S1.
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Figure 2. WT-H-Ras Knockdown Enhances DNA Damage in K-Ras Mut, but Not in K-Ras WT, Cancer Cells
(A) Quantification of gH2AX-positive cells in K-Ras Mut and K-Ras WT cancer cells uponWT-H-Ras knockdown. K-Ras Mut and K-Ras WT cells from cancers of
the colon (DLD1) and pancreas (Panc-1, AsPC-1, PL45, MIA PaCa-2, BxPC-3, and Hs-700T), depleted of WT-H-Ras, were costained for gH2AX and DAPI, and
the percentage of cells positive for gH2AX foci (>10 per cell) was determined. At least 500 cells were scored per condition. Data are presented relative to the
values obtained for scramble shRNA cells in each cell line, respectively. Error bars, mean ± SEM, n = 3, **p < 0.005, ***p < 0.0005. S-phase percentages as
determined by flow cytometry analysis of the percentage of BrdU-incorporating cells are indicated below the bar graphs.
(B) Representative images showing gH2AX levels in WT-H-Ras-suppressed DLD1 K-RasMut cells. Cells were costained for gH2AX and DAPI. Scale bars, 5 mm.
(C) Isoform-specific knockdown of H-Ras in the cancer cells lines shown in (A). * indicates Erk2 as a loading control instead of vinculin.
See also Figure S2.
Cancer Cell
Dependence of Mutant K-Ras Cancer Cells on WT-Rasbeing selectively dependent on WT-H-Ras for modulating DNA
damage and cell-cycle progression (Figures 2A–2C). A similar
dependency was observed upon knockdown of WT-N-Ras,
and no synergistic effect was observed when both WT-H-Ras
and WT-N-Ras were knocked down (Figures S2A–S2C). The
elevated gH2AX levels were not due to an accumulation of cells
in S-phase because there was no significant difference in the
S-phase profiles between control and WT-H-Ras, WT-N-Ras,
or WT-H- and N-Ras-suppressed cells (Figures 2A and S2B).
Of note, we have observed no correlation between enhanced
gH2AX levels due to WT-H- and/or N-Ras knockdown and the
proliferative rate or basal gH2AX levels of the cancer cells
analyzed (Figure S1D; data not shown). This suggests that the
elevated DNA damage induced by WT-H- and/or N-Ras knock-
down is not due to a faster proliferation rate or higher basal DNA
damage of K-Ras mutant cells but instead is a consequence of a
perturbed DDR. Moreover, knockdown of WT-H-Ras in mela-246 Cancer Cell 25, 243–256, February 10, 2014 ª2014 Elsevier Inc.noma cells that harbor an activating N-Ras mutation (NRas
Q61L) also enhanced gH2AX levels, indicating that WT-Ras
could be required for the regulation of the basal levels of DNA
damage in cancer cells with activating mutations in any of the
Ras isoforms (Figure S2E).
Dependence ofMutant K-RasCancerCells onWild-Type
H- and N-Ras for the Activation of the G2 DNA Damage
Checkpoint
To directly evaluate whether WT-H-Ras knockdown impacted
the activation of the DNA damage checkpoint, we subjected
K-Ras Mut cells to UV-C irradiation and monitored mitotic entry
at 1, 2, and 3 hr intervals after UV-C-induced damage. Panc-1
andDLD1-K-RasMut cells expressing scramble shRNA displayed
a block in mitotic entry in response to UV-C-induced DNA dam-
age, indicating a functional G2 DNA damage checkpoint (Figures
3A, 3B, and S3A). In contrast, progression into mitosis following
(legend on next page)
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Dependence of Mutant K-Ras Cancer Cells on WT-RasUV-C treatment was unperturbed in Panc-1 and DLD1-K-RasMut
cells depleted ofWT-H-Ras, indicating a defective G2DNA dam-
age checkpoint (Figures 3A and 3B). This defect was not specific
to UV-C-induced damage as Panc-1 (Figure 3C) and DLD1-
K-RasMut cells (Figure S3B) depleted of WT-H-Ras failed to
initiate and maintain cell-cycle arrest in response to the topo-
isomerase I inhibitor SN38. A similar defect was observed in
Panc-1 cells depleted of WT-N-Ras (Figure S3C).
A predictable outcome of a defective G2 DNA damage check-
point is entry into mitosis with unresolved DNA breaks following
damage (Jiang et al., 2009). In agreement with this prediction, a
significant fraction of WT-H- and/or N-Ras-depleted Panc-1 and
DLD1-K-RasMut cancer cells that entered mitosis following UV-C
exposure also stained positive for gH2AX (Figures 3D, 3E, and
S3D). Notably, no such differences were observed in K-Ras
WT cancer cell lines (Figures 3E and S3D). These data demon-
strate that WT-H- and/or N-Ras are critical for the establishment
of a functional G2 DNA damage checkpoint selectively in K-Ras
Mut cancer cells.
Wild-Type H- and N-Ras Knockdown Impairs Chk1
Activation in K-Ras Mutant Cancer Cells
To gain insight into themolecular basis for the perturbation of the
G2 DNA damage checkpoint by WT-H/N-Ras knockdown, we
examined the DNA-damage-specific activation of ATR/Chk1
and ATM/Chk2 in response to SN38 or UV-C treatment (Bartek
and Lukas, 2003; Zhou and Elledge, 2000). Notably, WT-H-Ras
knockdown was accompanied by a defective Chk1 activation
in response to either SN38 or UV-C treatment in K-Ras Mut
cell lines Panc-1 and DLD1-K-RasMut (Figures 3F, S3E, and
S3F), and MIA PaCa-2 (Figure S4A) as evidenced by impaired
phosphorylation of Chk1 at Ser 317 and Ser 345. The require-
ment for WT H-Ras for ATR/Chk1 activation was a specific prop-
erty of K-Ras mutant cells as WT-H-Ras knockdown had no
effect on Chk1 activation in the K-Ras WT cell lines BxPC-3
and DLD1-K-RasKO (Figures 3F, S3E, and S3F). The defect in
Chk1 activation upon WT H-Ras knockdown in K-Ras mutant
cells was also reflected in the impaired inhibitory phosphoryla-
tion of Cdk1 at Tyr 15 (Figures 3F and S3E). By comparison,
Chk2 activation, as monitored by phosphorylation of Chk2 at
threonine 68 (Thr68), was not affected byWT-H-Ras knockdown
in either K-Ras Mut (Panc-1) or K-Ras WT (BxPC-3) cancer cell
lines (Figures 3F and S3E). Of note, Chk2 protein levels inFigure 3. K-Ras Mutant Cancer Cells Selectively Depend on WT-H-R
Checkpoint
(A) Representative FACS plots showing the P-HH3-positive population in untreate
scramble (Scr) or WT-H-Ras shRNA (n = 3). The boxed area represents the % P
(B) Quantifications of the experiments described in (A) for K-Ras Mut cell lines. Da
or WT-H-Ras shRNA) untreated cells.
(C) FACS histograms showing the cell-cycle profile of WT-H-Ras-suppressed P
indicated. Data are representative of three independent experiments.
(D and E) K-RasMut and K-RasWT cancer cells expressing the indicated shRNAs
mitotic cells, and costained for P-HH3 (blue) and gH2AX (green). Representative im
are shown in (D). Scale bar, 10 mm. Quantifications of the fraction of mitotic cells (
per cell) are shown in (E). Data are presented as relative to the values obtained fo
experiment. S-phase percentages are indicated below the bar graphs.
(F) Representative immunoblots for the indicated proteins in mock or SN38 treated
are shown.
All experiments: error bars, mean ± SEM, n = 3, **p < 0.005, ***p < 0.0005. See a
248 Cancer Cell 25, 243–256, February 10, 2014 ª2014 Elsevier Inc.DLD1 cells were too low to reliably measure its activation status.
WT-N-Ras knockdown also led to a selective and similar
impairment of ATR/Chk1 activation in K-Ras mutant cells (Fig-
ure 4). Taken together, these results indicate that the defective
G2 DNA damage checkpoint caused by WT-H/N-Ras knock-
down in K-Ras mutant cells is due to the failure to properly acti-
vate Chk1.
Wild-Type H- and N-Ras Negatively Regulate MAPK and
Akt Signaling to Control Chk1 Phosphorylation
The Ras effector signaling pathways, Raf/Erk and PI3K/Akt, have
been shown to play a key role in Chk1 activation and the G2/M
phase of the cell cycle. PI3K/Akt was reported to override
DNA-damage-induced G2 arrest through repression of Chk1
activation via Akt-mediated inhibitory phosphorylation of Chk1
at Ser 280 (King et al., 2004; Puc and Parsons, 2005; Shtivelman
et al., 2002). More recently, the Raf/MAPK pathway has been
shown to impair Chk1 activity through Chk1 Ser 280 phosphor-
ylation by MAPK-activated protein kinase RSK (p90 ribosomal
S6 kinase) (Li et al., 2012; Ray-David et al., 2012). As wild-type
Ras proteins have been reported to antagonize Ras effector
signaling output in cancer cells that harbor mutant Ras (Young
et al., 2012), we next investigated whether impaired Chk1 activa-
tion upon WT-H- or N-Ras knockdown was due to enhanced
activation of Ras effector pathways. Knockdown of WT-H-
or N-Ras in mutant K-Ras cancer cells was associated with
elevated Erk/p90RSK and Akt activation, which correlated with
enhanced inhibitory phosphorylation of Chk1 at Ser 280, both
in the basal state and following SN38-induced DNA damage
(Figures 4A and 4B). Conversely, suppression of Erk or Akt
signaling via treatment with MAPK or Akt inhibitors overturned
the hyperphosphorylation of Chk1 at Ser 280 in WT-H- or
N-Ras-depleted mutant K-Ras cancer cells. Importantly, under
these conditions, the activation of Chk1 in response to SN38-
induced DNA damage was restored as shown by Chk1 Ser
317 phosphorylation (Figure 4C). Altogether, these results sup-
port a model whereby in K-Ras mutant cells, the downregulation
WT-H/N-Ras leads to the enhancement of Erk/p90RSK and Akt
signaling, which in turn represses Chk1 activation through Chk1
Ser 280 phosphorylation.
To rule out the possibility that WT-H/N-Ras may also specif-
ically prevent Chk1 Ser 280 phosphorylation, we generated
an isogenic derivative of the DLD1-K-RasMut cell line that canas for the Activation of the ATR-Chk1-Mediated G2 DNA Damage
d () and (+) UV-C treated (at 1 and 3 hr posttreatment) Panc-1 cells expressing
-HH3-positive cells.
ta are presented as relative to the values obtained for the respective (scramble
anc-1 cells following SN38 (4 nM) treatment. The S and G2/M fractions are
were treated with UV-C, placed in nocodazole containingmedia for 4 hr to trap
munofluorescence images of mitotic DLD1 K-RasMut cells treated as indicated
P-HH3) expressing the indicated shRNAs that are positive for gH2AX foci (>10
r the scramble shRNA (Scr sh) cells. At least 50 mitotic cells were analyzed per
(4 nM SN38 for 2 hr) Panc-1 (K-Ras Mut) and BxPC-3 (K-Ras WT) cancer cells
lso Figure S3.
Figure 4. WT-H- and N-Ras Knockdown Enhances Erk/p90RSK and PI3K/Akt Activation to Promote Phosphorylation of Chk1 at Ser 280 and
Inhibit its Activity
(A) Activation status of Erk, p90RSK, Akt, and Chk1 in WT-H/N-Ras-suppressed Panc-1 cells in the basal state or upon SN38-induced damage (8 nM SN38
for 2 hr).
(B) The fold change in the amount of pErk1/2, p-p90RSK Thr573, pAkt Thr308, pChk1 S280, and pChk1 S317 in WT-H/N-Ras shRNA as compared to scramble
shRNA-expressing cells is indicated. Quantification of pErk1/2, pAkt Thr308, pChk1 S280, pChk1 S317, and p-p90RSK Thr573 was carried out by densitometry
scanning and normalized to the total levels of Erk, Akt, and Chk1, respectively, and vinculin for p-p90RSK Thr573. Error bars, mean ± SD, n = 3, *p < 0.05, **p <
0.005, ***p < 0.0005, ****p < 0.00005.
(legend continued on next page)
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Dependence of Mutant K-Ras Cancer Cells on WT-Rasinducibly express GFP-H-RasG12V upon doxycycline adminis-
tration (DLD1-K-RasMut Flip-IN TREX GFP-H-RasV12) (Girdler
et al., 2006). As illustrated in Figure 4D, expression of GFP-
H-RasG12V at sub-endogenous levels led to a concomitant
increase in Erk and AKT signaling despite the presence of WT-
H/N-Ras in these cells. Moreover, this was accompanied by
the phosphorylation of Chk1 at the inhibitory site Ser 280 and
an impairment of Chk1 phosphorylation at the activation sites
Ser 317 and Ser 345 (Figure 4D). Altogether, our data are consis-
tent with a model in which the enhanced phosphorylation of
Chk1 at Ser 280 and inhibition of Chk1 activity observed under
conditions of WT-H-Ras deficiency in mutant K-Ras cells is a
consequence of an increase in Erk/Akt signaling.
If the activation of Chk1 is directly linked to the presence of
mutant K-Ras, then the acute expression of mutant K-Ras in
an otherwise K-Ras wild-type cancer cell line should render
Chk1 activation in these cells dependent on WT-H/N-Ras. To
test this idea, we silenced WT-H-Ras in BxPC-3 cells (K-Ras
WT) that had been engineered to inducibly express K-RasG12V
(BxPC-3 K-RasV12) (Figure S4C). Whereas, knockdown of WT-
H-Ras in the parental BxPC-3 cell line had no effect on Chk1
Ser 280 phosphorylation and Chk1 activation (Figures 3F and
S4B), knockdown of WT-H-Ras in BxPC-3 cells induced to ex-
press K-RasG12V led to elevated Erk activation, induction of
Chk1 Ser 280 phosphorylation, and impairment of Chk1 phos-
phorylation at Ser 317 (Figure S4D). These results suggest that
the hyperactivation of Erk/Akt pathways, the enhancement of
Chk1 Ser 280 phosphorylation, and the impairment of Chk1
activation induced by WT-H-Ras knockdown represent a set of
responses that are specifically dictated by the mutational status
of K-Ras.
Mutant K-Ras Cancer Cells Depleted of Wild-Type
H- and N-Ras Are Highly Sensitive to DNA Damage-
Inducing Agents
The underlying premise for the therapeutic use of DNA-
damaging agents is that susceptibility of cancer cells is linked
to the lack of G1/S and G2 checkpoints (Ma et al., 2011; Zhou
and Bartek, 2004). Therefore, we reasoned that the abrogation
of the ATR/Chk1-induced DNA damage checkpoint in K-Ras
mutant cells by WT-H- and/or N-Ras knockdown could enhance
the therapeutic efficacy of DNA damaging agents. Assessment
of cell viability following treatment with SN38 indicated that the
K-Ras mutant cells DLD1 K-RasMut and Panc-1-expressing
shRNAs targeting H-Ras were on average 90-fold and 50-
fold more sensitive to SN38, respectively, as compared to
DLD1 K-RasMut and Panc-1 cells expressing scramble shRNA
(Figure 5A). Similarly, WT-H-Ras knockdown sensitized these
cells (13-fold for DLD1 K-RasMut and 25-fold for Panc-1) to
the DNA intrastrand crosslinker oxaliplatin (Figure 5B). Notably,(C) Panc-1 cells expressing the indicated shRNAswere treatedwith 8 nMSN38 for
PI3K inhibitor (LY294002, 5 mM). WCLs were analyzed to determine ERK/p90R
activation status.
(D) Isogenic derivatives of DLD1 K-RasMut cells engineered to inducibly express G
doxycycline were induced for 0, 2, or 4 hr and subjected to SN38 (8 nM) for 2 hr (fo
Dox induction, SN38 was added 2 hr postinduction and the cells were incubated fo
shown. Arrowhead indicates GFP-H-RasG12V, and * indicates endogenous H-R
See also Figure S4.
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did not lead to a sensitization to SN38 or oxaliplatin treatment
(Figures 5A and 5B). Analysis of the apoptotic index, as
measured by FACS detection of cleaved caspase 3-positive
cells, demonstrates an exacerbation of cell death by WT-
H-Ras knockdown in response to SN38 treatment (Figures 5C
and 5D). Knockdown of WT-N-Ras also sensitized these cells
to SN38 and oxaliplatin (Figure S5). Together, these results
show that WT-H-Ras or N-Ras knockdown specifically sensi-
tizes K-Ras Mut cancer cells to DNA damaging agents. A similar
sensitization pattern was observed upon the treatment of cells
with the Chk1/Chk2 inhibitor AZD7726 (Figures 6A, 6B, and
S6), supporting the hypothesis that WT-H/N-Ras downregula-
tion selectively sensitizes K-Ras mutant cells to DNA damage-
inducing agents by abrogating Chk1 activity.
Knockdown of Wild-Type H-Ras Sensitizes K-Ras
Mutant Tumors to DNA Damage-Inducing
Chemotherapy and Leads to Tumor Regression
To test the in vivo effects of WT-H-Ras knockdown on the sensi-
tivity of K-Ras mutant tumors to DNA damaging agents, we
established xenografts of DLD1-K-Ras mutant cells that induci-
bly express WT-H-Ras shRNA upon exposure to doxycycline in
athymic nu/nu mice. Administration of doxycycline or vehicle
was initiated after tumors had reached 100 mm3. Seven days
postinduction (tumor size 250 mm3), efficient knockdown of
WT-H-Ras was confirmed in the established tumors, and treat-
ment with irinotecan (CPT), a topoisomerase I inhibitor that is
FDA-approved for the treatment of colorectal cancer, was initi-
ated (Figure S7A). In the absence of treatment with irinotecan,
tumors arising from the WT-H-Ras-suppressed cells grew simi-
larly to those arising fromuninduced control cells (Figures 7A and
7B). Thus, distinct from our in vitro studies, WT-H-Ras knock-
down in vivo was not associated with any delay in growth or
mitotic progression under these conditions (Figures 7A, 7D,
and 7E). However, similar to our observations in the synchroniza-
tion studies, we did note an elevation in aberrant mitotic figures
(chromosome misalignment and lagging chromosomes), which
is an indication of perturbed mitosis (Figure 1G; data not shown).
Hence, the lack of a higher mitotic index despite aberrant mitosis
may reflect clearance of the aberrant mitotic cells in the in vivo
setting. In agreement with previously reported studies, treatment
with irinotecan alone resulted in a reduction of tumor growth (Fig-
ures 7A and 7B) (Harris et al., 2005; Zabludoff et al., 2008).
Notably, 5 days following the termination of irinotecan adminis-
tration, WT-H-Ras-suppressed tumors had undergone regres-
sion, which was maintained for the duration of the study, up to
18 days posttreatment (Figures 7A and 7B). In contrast, the con-
trol irinotecan-treated tumors showed in large part a modest
growth over the same time period (Figure S7B). Consistent2 hr and in the presence or absence of theMAPK inhibitor (U0126, 10 mM) or the
SK or Akt inhibition and their respective effect on Chk1 phosphorylation and
FP-H-RasG12V (DLD1 K-RasMut Flp-IN TREX GFP-H-RasV12) upon addition of
r the 2 hr Dox induction, Dox and SN38 were added simultaneously; for the 4 hr
r an additional 2 hr). Representative immunoblots for the indicated proteins are
as.
Figure 5. Knockdown of WT-H-Ras Selectively Sensitizes Mutant K-Ras Cancer Cells to DNA Damage
(A and B) MTT cell viability assays of K-Ras Mut cancer cells (DLD1 K-RasMut and Panc-1) and K-Ras WT cancer cells (DLD1 K-RasKO and BxPC-3) induced to
express scramble or WT-H-Ras shRNAs, and following a 72 hr treatment with SN38 (A) or oxaliplatin (B). Viable fraction is expressed as a percentage of the
viability values obtained for the respective untreated conditions. p < 0.005 for H-Ras sh 1 or H-Ras sh 3 plus SN38 or oxaliplatin versus Scr sh plus SN38 or
oxaliplatin in K-Ras mutant cells, respectively.
(C) Detection of cell death by FACS analysis of the Nucview Alexa-488 caspase 3-positive population in SN38-treated K-RasMut cells. Representative profiles of
Nucview Alexa-488 caspase 3 fractions in DLD1 K-RasMut cells inducibly expressing scramble or WT-H-Ras shRNAs and treated with SN38 (16 nM) for 72 hr.
(D) Quantification of cell death as determined by the Nucview Alexa-488 caspase 3-positive fraction inWT-H-Ras-depleted K-Rasmutant cells treated with SN38
as in (C). Data are presented relative to the values obtained for the respective scramble shRNA-expressing cells. Error bars, mean ± SEM, n = 3, **p < 0.005.
See also Figure S5.
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Dependence of Mutant K-Ras Cancer Cells on WT-Raswith our cell-based studies, abrogation of WT-H-Ras in mutant
K-Ras tumors led to Erk and Akt hyperactivation and the inhibi-
tion of Chk1 activation, as reflected by an elevated Chk1 Ser 280
phosphorylation and an impaired Chk1 Ser 317 phosphorylation
in both mock and irinotecan-treated tumors (Figure 7C). Assess-
ment of the extent of apoptosis revealed that the combination of
WT-H-Ras knockdown and irinotecan treatment induced a sig-Cnificant increase in tumor cell apoptosis compared to WT-
H-Ras knockdown or irinotecan treatment alone (Figures 7D
and 7E). Importantly, irinotecan treatment failed to induce cell-
cycle arrest of WT-H-Ras-suppressed tumors as evident by
the significant increase in the number of cells staining positive
for phosphorylated histone H3 compared to WT-H-Ras-intact
tumors (Figures 7D and 7E). These results indicate thatancer Cell 25, 243–256, February 10, 2014 ª2014 Elsevier Inc. 251
Figure 6. The Chk1/Chk2 Inhibitor AZD7762
Potentiates SN38 Cytotoxicity Selectively in
K-Ras Mutant Cancer Cells
Viable fraction is expressed as a percentage
mean ± SEM of the viability values obtained for
respective vehicle-only treated conditions from
three independent experiments each performed in
triplicate.
(A and B) K-Ras mutant cancer cells (DLD1
K-RasMut, Panc-1, and MIA PaCa-2) (A) or K-Ras
WT cancer cells (DLD1 K-RasKO and BxPC-3) (B)
were treated with SN38 alone or a combination of
SN38 and AZD7762 (SN38 + AZD7762) for 48 hr at
the indicated concentrations and analyzed for cell
viability by the MTT assay. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001 for SN38 + AZD7762-
treated versus SN38-treated alone.
(C) K-Rasmutant and K-RasWT cells were treated
with AZD7762 alone for 48 hr and assessed for cell
viability by the MTT assay.
See also Figure S6.
Cancer Cell
Dependence of Mutant K-Ras Cancer Cells on WT-RasWT-H-Ras knockdown in K-Ras mutant cells compromises the
DNA damage checkpoint-mediated cell-cycle arrest in vivo.
To further substantiate the in vivo analyses of the conse-
quences of WT-H-Ras knockdown, we administered irinotecan
or vehicle to xenograft tumors derived from either MIA PaCa-2
(K-RasMutant) or BxPC-3 (K-RasWT) cells that were engineered
to inducibly (+Dox) express WT-H-Ras shRNA (Figures S7C and
S7D). Similar to DLD1-K-RasMut xenografts, combination of WT-
H-Ras knockdown and irinotecan treatment led to MIA PaCa-2
tumor regression, but irinotecan alone led to a growth delay
and WT-H-Ras knockdown alone had no effect (Figure S7C).
Importantly, we found no synergy between WT-H-Ras knock-
down and irinotecan treatment in BxPC-3 xenograft tumors (Fig-
ure S7D). Collectively, these observations establish a role for
WT-H-Ras in maintaining a functional Chk1-dependent DNA
damage checkpoint in established K-Ras mutant tumors.
DISCUSSION
Effective targeting of oncogenic K-Ras-driven tumors has re-
mained a major challenge in cancer therapy. Considerable evi-
dence indicates that cancer cells develop dependencies on
normal functions of certain genes that can potentially be ex-
ploited to improve therapeutic strategies (De Raedt et al.,
2011; Kumar et al., 2012; Luo et al., 2009a, 2009b). In the present
study, we demonstrate that K-Ras mutant cancers display a252 Cancer Cell 25, 243–256, February 10, 2014 ª2014 Elsevier Inc.dependency on WT-H/N-Ras for the acti-
vation of the ATR/Chk1-mediated DNA
damage response (DDR) and therefore
can be sensitized to DNA-damaging
chemotherapeutics through the suppres-
sion of WT-H/N-Ras. The activation of
DDR has been shown to play distinct
context-dependent roles in the course
of malignant transformation (Toledo
et al., 2011a). In premalignant lesions,
DDR activation is triggered by oncogenic
stress and commonly leads to cell deathor senescence, thereby functioning as an intrinsic barrier to
malignancy (Bartkova et al., 2005; Gilad et al., 2010; Schoppy
et al., 2012). Full malignant transformation, however, is accom-
panied by a weakening of the DDR barrier through the selective
acquisition of mutations within critical DDR signaling modules
(for example, p53 mutations and abrogation of ATM/Chk2/p53
signaling). As such, advanced tumors become highly reliant on
the remaining functional DDR pathway (ATR/Chk1) for coping
with the high levels of oncogene-induced genotoxic stress. In
this context, the role of WT-H/N-Ras in coordinating the activa-
tion of ATR/Chk1 is critical for supporting the tumorigenic
phenotype of K-Ras mutant tumors by preventing catastrophic
DNA damage and enhancing tumorigenic fitness and survival.
Consistent with this model, wild-type Ras has been shown to
play a tumor-promoting role in cell lines from established tumors
(Young et al., 2012).
Our results identify a role for WT-H/N-Ras in facilitating Chk1
activation by suppressing the Erk/p90RSK and PI3K/Akt path-
ways that inhibit Chk1 via Ser 280 phosphorylation. The capacity
of WT-Ras to negatively regulate effector pathway signaling in
mutant Ras cancer cells is consistent with earlier reports
showing that the levels of WT-Ras proteins in mutant Ras cancer
cell lines are inversely correlated to the activation status of Ras-
effector molecules (Young et al., 2012; Zhang et al., 2001). It is
noteworthy that the knockdown of wild-type isoform alone is suf-
ficient to hyperactivate Erk and Akt and inhibit Chk1 activity and
Figure 7. WT-H-Ras Knockdown in Established Mutant K-Ras Tumors Impairs Cell-Cycle Arrest Induced by DNA Damaging Chemothera-
peutic Agents and Leads to Tumor Regression
(A) Waterfall plot and scatter plot showing percentage change in the volume of subcutaneous DLD1 K-RasMut tumors in nude mice 5 days after the last dose of
irinotecan (CPT) administration. Percentage change was determined relative to the tumor volume at the start of irinotecan (CPT) treatment for each individual
tumor. Mice engrafted with 2 3 106 DLD1 K-RasMut cells stable for the doxycycline-inducible H-Ras 1 sh were given either doxycycline or vehicle-only (0.5%
sucrose) as a control via their drinking water once tumors attained100 mm3. Irinotecan (CPT) administration (50 mg/kg every other day for 6 days [q2 dx3]) was
initiated when tumors reached 250 mm3. Error bars, mean ± SEM.
(B) Representative xenograft tumors are shown.
(C) WCLs of tumor tissue obtained from the indicated animals 24 hr after the initiation of irinotecan (CPT) administration were immunoblotted with antibodies for
the indicated proteins.
(legend continued on next page)
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Cancer Cell
Dependence of Mutant K-Ras Cancer Cells on WT-Rascheckpoint function. This suggests a tightly controlled threshold
for the WT-H/N-Ras-mediated attenuation of Ras-effector sig-
naling in mutant K-Ras cancers. The mechanisms underlying
theWT-H/N-Ras-mediated antagonism of Ras effector signaling
in mutant K-Ras cancers remain to be delineated. Of potential
relevance to this question are the seemingly contradictory ob-
servations that whereas the knockdown of WT-H/N-Ras in
mutant K-Ras cancer cells induces Erk and Akt hyperactivation,
the knockdown of Sos1, a guanine nucleotide exchange factor
for Ras GTPases, instead impairs Erk and Akt activity (Jeng
et al., 2012). A fundamental difference between these two sce-
narios is that whereas Sos knockdown would affect the levels
of GTP-bound Ras, the knockdown of WT-H/N-Ras would inev-
itably lessen both GDP and GTP-bound Ras levels. Because the
WT-isoforms exist predominantly in the GDP-bound form,
knockdown of WT-H/N-Ras is likely to significantly alter the stoi-
chiometry of GDP- to GTP-Ras molecules. This may provide a
plausible explanation for the observed hyperactivation of Erk
and Akt, as GDP-bound Ras molecules have been suggested
to play an inhibitory role in Ras signaling (Singh et al., 2005).
Furthermore, in the case of Raf, activation depends on Ras-
mediated homo- and/or heterodimerization of Raf proteins,
which likely require at least two Ras-GTP molecules (Heidorn
et al., 2010; Inouye et al., 2000; Poulikakos et al., 2011; Rush-
worth et al., 2006; Weber et al., 2001). Because Ras dimerization
appears to be constitutive and nonselective for GDP or GTP-
bound Ras, depletion of GDP-bound Ras, as in the case of
knockdown of WT-H-Ras or N-Ras, would stoichiometrically
favor Ras-GTP dimer formation and consequently lead to Raf
hyperactivation (Heidorn et al., 2010; Inouye et al., 2000).
There is now a large body of pre-clinical evidence showing that
inhibition of the ATR/Chk1 pathway enhances the efficacy of
standard chemotherapy. Indeed, several Chk1 inhibitors are
being tested in clinical trials (Ma et al., 2012). As such, the ability
of WT-H/N-Ras to determine Chk1 activation in mutant K-Ras
tumors may warrant further exploration into the development
of a therapeutic approach that utilizes inhibition of wild-type
Ras-ATR/Chk1 signaling in combination with DNA damaging
agents for the selective targeting of K-Ras-driven cancers.
EXPERIMENTAL PROCEDURES
Cell Culture and Lentiviral Transduction
Human pancreatic cancer cell lines Panc-1, PL45, AsPC-1, CFPAC-1, MIA
PaCa-2, BxPC-3, and Hs700T were obtained from the American Type Culture
Collection. The isogenic colon cancer cells DLD1-K-RasMut and DLD1-K-
RasKO were a kind gift from Dr. Mark Philips. Lentiviral particles were gener-
ated in accordance with standard protocols. For knockdown experiments,
cells were transduced with lentiviral particles (multiplicity of infections [moi]
for Hs700T, 15; all other cell lines, 7) containing pTripz scramble shRNA,
H-Ras shRNA, or N-Ras shRNA and selected with puromycin (Calbiochem;
for AsPC-1, 4 mg/ml; for all others, 2 mg/ml) for 3 days. Unless otherwise indi-
cated, all experimentswere performed on day 4 of doxycycline (1 mg/ml) induc-
tion. DLD1 K-RasMut Flip-IN TREX GFP-H-RasV12 cells were generated
through Flp recombinase-mediated homologous recombination between the
FRT sites in the DLD1 K-RasMut cell line and the pcDNA3/FRT/TO/GFP-(D and E) Tumor sections from mice in (A) treated as indicated were stained for h
Representative images are shown in (D), and quantifications are shown in (E). Sc
field of view (FOV) at 203 magnification. Error bars, mean ± SD, n = 3 mice per
See also Figure S7.
254 Cancer Cell 25, 243–256, February 10, 2014 ª2014 Elsevier Inc.HRasG12V expression vector. To generate BxPC-3-K-RasV12 cells, BxPC-3
cells were transduced with a TET-inducible lentiviral vector to express
K-RasG12V, pLenti-TO-K-RasG12V (moi = 1). Following puromycin selection,
cells that had efficiently integrated the K-RasG12V lentiviral construct (BxPC-
3-K-RasV12) were expanded and subsequently transduced with a pTRIPZ-
H-Ras sh construct. As both vectors are Dox inducible, induction of the
expression of K-RasV12 also induces the knockdown of WT-H-Ras. Following
a 48 hr induction, BxPC-3-K-RasV12 cells that also expressed the H-Ras sh
were obtained by fluorescent sorting (RFP: pTRIPZ-H-Ras sh also expresses
RFP upon Dox induction). The obtained cells were then cultured for an addi-
tional 48 hr in the presence of Dox and assayed for Chk1 activation upon treat-
ment with SN38.
Cell Viability Assays
For viability assays, cells were treated with doxycycline to induce shRNA
expression for 4 days and then seeded at a density of 4,000 cells/well in a
96-well plate in doxycycline containing media. Twenty-four hours postplating,
SN-38 (Tocris Biosciences), oxaliplatin (Tocris Biosciences), or vehicle was
added. Following a 72 hr treatment, cell viability was assessed by the MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; Sigma-Aldrich)
assay in accordance with the manufacturer’s protocol. Viable fraction is ex-
pressed as the percentage of vehicle-treated control cells. EC50 was calcu-
lated using Graphpad Prism (v. 4.0) software.
Cell Synchronization and Flow Cytometry
Cells were synchronized at the G1/S transition by a double thymidine block.
Cells were treated with 2 mM thymidine for 22 hr and released from thymidine
block by washing twice with PBS, followed by incubation in fresh medium.
Fourteen hours after release, thymidine was added for another 20 hr. Induction
of H-Ras shRNA expression was initiated with the first thymidine block. For the
G2/M checkpoint analysis in response to UV-C, cells were irradiated with
UV-C (25 J/m2) during the exponential growth phase. Cells were harvested
1, 2, and 3 hr later, fixed with ice-cold 80% ethanol/PBS, and incubated over-
night at 20C. Fixed cells were washed with PBS and permeabilized with
0.25% Triton X-100/PBS on ice for 10 min. Cells were stained with anti-
phospho histone H3 to detect mitotic cells and TO-PRO 3 for DNA content.
For G2/M checkpoint activation in response to SN-38, cells were treated
with 4 nM SN-38 and fixed at the indicated time points. Staining for cleaved
caspase 3-positive cells was performed using the Nucview-488 Caspase 3
Kit (Biotium). Flow cytometry was performed on an LSRII (BD Biosciences)
at NYU School of Medicine Flow Cytometry Core Facility, and data were
analyzed using FlowJo software.
Animal Studies
For xenograft studies, we subcutaneously implanted 23 106 DLD1 K-RasMut,
MIA PaCa-2, or BxPC-3 cells stable for pTripz-H-Ras shRNA (1:1 in Matrigel,
BD Biosciences) in both flanks of 8-week-old female athymic nude (NCRNU,
Taconic) mice. When tumor size reached100 mm3, mice were given drinking
water containing either doxycycline (0.2 mg/ml)/0.5% sucrose or 0.5%
sucrose alone. Water was replaced every 3 days. Tumor volume was deter-
mined using electronic calipers to measure length (l), width (w), and the
formula (w2 3 l)/2. Tumor volume was measured twice a week. We treated
mice bearing H-Ras-depleted (dox/sucrose) or H-Ras-intact (sucrose) DLD1
K-RasMut tumors with either irinotecan or vehicle, once tumors reached
250 mm3. Irinotecan hydrochloride (CPT) powder was dissolved into solution
as previously described (Harris et al., 2005; Zabludoff et al., 2008). This solu-
tion was diluted with 5% dextrose for intraperitoneal (i.p.) injection at a dose
of 50 mg/kg every other day for 3 rounds of treatment (q2 dx3). Irinotecan,
or the combinatorial H-Ras knockdown and irinotecan treatments, were well
tolerated as no weight loss above 10% body mass was observed. Body
mass was measured using an electronic scale every 2 days. The percent
change in tumor volume from day 0 of irinotecan treatment to tumor volumeematoxylin and eosin (H&E), anti-cleaved caspase 3, or anti-P-HH3 antibody.
ale bars, 40 mm. Cleaved caspase 3 or P-HH3-positive cells were counted per
group, four FOV per mouse. ****p < 0.0001.
Cancer Cell
Dependence of Mutant K-Ras Cancer Cells on WT-Ras5 days after the last dose of irinotecan administration was measured. Mice
were euthanized by carbon dioxide-induced narcosis. To prepare lysates,
tumor tissue was homogenized in RIPA buffer and sonicated to shear genomic
DNA. All animal work was approved by New York University Langone Medical
Center Institutional Animal Care and Use Committee.
Statistical Analyses
Data were analyzed by the Graphpad Prism built-in test (unpaired, two-tailed),
and results were considered significant at p < 0.05.
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